Our Mission
Transform patient outcomes by bringing the cellular biology of depression into its diagnosis and treatment
Products
Clinical Applications:
Years of research have yielded the first biomarkers expected to quantitatively diagnose depression and rapidly predict medication effectiveness. With quantitative results in days, Pax Neuroscience’s patented MoodMark® platform uses a sample from a simple office-based blood draw to potentially transform a patient’s depression management.
MoodMark® Dx
MoodMark® Rx
MoodMark® Px
(in development)
Diagnoses presence and severity of depression within days
Tests antidepressant effectiveness within days
Personalizes antidepressant prescribing within days
Pharmaceutical Applications:
Pax offers a suite of potential pharmaceutical applications.
MoodMark® LS
MoodMark® TE
MoodMark® PS
Screens products within pharmaceutical companies’ drug libraries for antidepressant effect potential
Confirms that subjects selected for clinical trials are clinically depressed and rates their severity
Objectively measures clinical trial subjects’ therapy response endpoint within as little as one week from starting dosage
Leadership
Management Team

Barry R. Frankel, MBA
Chief Executive Officer
Over 40 years experience in life science industry, including company formation, operations, strategy, licensing, mergers, acquisitions, and commercialization. Five successful exits to date.

Robert Friesen, MA, MHA
Chief Operating Officer
Over 40 years in healthcare with experience in strategy, M&A, partnerships, operations, providers, payors, and early/growth-stage companies, as well as clinical psych inpatient and outpatient settings.

Helene J. Shambelan, JD
Founder, President
Former law professor focused on corporation and securities law, concentrating for over a decade on the areas of health and biotechnology.

Mark M. Rasenick, PhD
Founder, Chief Scientific Officer
Distinguished professor of physiology and psychiatry, specializing in the biology of mood disorders, and long-time advisor to policymakers on mental health.

Steven D. Targum, MD
Chief Medical Officer
Former professor and chair of psychiatry with over three decades of expertise in clinical trial methodology and drug development strategy.
Scientific Advisory Board

Mark M. Rasenick, PhD
Founding Member

Paul Billings, MD, PhD
Founding Member

Eric Nestler, MD, PhD

Mark Rapaport, MD

Natalie Rasgon, MD, PhD

Alan F. Schatzberg, MD

Steven Targum, MD

Madhukar Trivedi, MD